Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions

Formulated Posterior Subtenon Triamcinolone (PSTA) Injection Versus Posterior Subtenon Triamcinolone Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05385562

Enrollment

Registered

2022-05-23

Start date

2020-01-02

Completion date

2022-05-10

Last updated

2022-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macula Edema

Brief summary

The aim of this study is to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone in the management of macular edema secondary to non-ischemic retinal vein occlusions, either central or branch.

Interventions

DRUGTriamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate

formulated with sodium hyaluronate and chondroitin sulfate

DRUGTriamcinolone Acetonide alone

Triamcinolone Acetonide alone

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation * CMT ≥ 250 µ. * Willing to participate in the study

Exclusion criteria

* Unwilling to participate in the study. * Ischemic RVO * Prior laser treatment * Glaucoma/Ocular Hypertension * Cataract which lead to difficulty in the evaluation of macula * Vitreous hemorrhage * Macular ischemia * Iris neovascularisation * patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.

Design outcomes

Primary

Measure	Time frame	Description
Best-corrected visual acuity (BCVA)	Baseline	will be measured with the Snellen chart
central macular thickness ( CMT)	at baseline	CMT will be measured with OCT

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026